- Stock: In Stock
- Brand: Incepta Pharmaceuticals
- Product ID: Entecavir
100% Secure Payment
Description
Entecavir is a guanosine nucleoside analogue with activity against HBV polymerase. Entecavir functionally inhibits all activities of the HBV polymerase (reverse transcriptase).
Indications
Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevation in serum aminotransferases (ALT or AST) or histologically active disease.
Dosage & Administration
The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naive adults and adolescents 16 years of age is 0.5 mg once daily. For Lamivudine-refractory or known Lamivudine or Telbivudine resistance mutations, the recommended dose of Entecavir is 1 mg once daily. For patients with decompensated liver disease (adult) the recommended dose of Entecavir is 1 mg once daily. Entecavir should be administered on an empty stomach (at least 2 hours after a meal or 2 hours before the next meal).
Dose Adjustment in Renal impairment: Dose adjustment is recommended for patients with creatinine clearance <50 mL/min.
Dosing interval adjustment of Entecavir in patients with renal impairment
| Creatinine clearance(mL/min) | >= 50 | 30 to < 50 | 10 to < 30 | < 10 Hemodialysis or CAPD |
|---|---|---|---|---|
| Recommended dose and dosing interval | 0.5 mg every 24 hours | 0.5 mg every 48 hours | 0.5 mg every 72 hours | 0.5 mg every 7 days |
Pediatric Use: Safety and effectiveness of Entecavir in pediatric patients below the age of 16 years have not been established.
Geriatric Use: Clinical studies of Entecavir did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. But care should be taken in dose selection, and it may be useful to monitor renal function.
Side Effects
The most common adverse events are headache, fatigue, dizziness and nausea.
Precautions
Lactic acidosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals.
Exacerbations of hepatitis after discontinuation of treatment: Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including Entecavir.
Use in Pregnancy & Lactation
Pregnancy: There are no data on the effect of Entecavir on transmission of HBV from mother to infant. Therefore, appropriate care should be taken.
Lactation: It is not known whether it is excreted in human milk. Mothers should be instructed not to breast feed if they are taking Entecavir.
Over Dose
There is no experience of Entecavir overdosage reported in patients.
Commercial Pack
Barcavir 0.5 : Each box contains 1 blister strip of 10 tablets.
Barcavir 1: Each box contains 1 blister strip of 10 tablets.
